Baylor University Medical Center Proceedings January 2014, Volume 27, Number 1

4. 5. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodneﬁeld JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ 3rd, Rajkumar SV. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007;356(25):2582–2590. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M; International Myeloma Working Group. Monoclonal gammopathy of undetermined signiﬁcance (MGUS) and smoldering 6. 7. 8. (asymptomatic) multiple myeloma: IMWG consensus perspectives, risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24(6):1121–1127. He Y, Wheatley K, Clark O, Glasmacher A, Ross H, Djulbegovic B. Early versus deferred treatment for early stage multiple myeloma. Cochrane Database Syst Rev 2003;(1):CD004023. Korbet SM. Treatment of primary FSGS in adults. J Am Soc Nephrol 2012;23(11):1769–1776. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011;8(8):479–491. Acknowledgment of reviewers for BUMC Proceedings, volumes 23–26 O ur thanks to those who reviewed and critiqued manuscripts submitted to Baylor University Medical Center Proceedings for publication in volumes 23 through 26. Reviewing scientiﬁc papers is an often unrecognized, arduous, and time-consuming task. We are grateful to our editorial board members and to the following additional reviewers for contributing their valuable comments and suggestions. Carol Adair, MD Brady Allen, MD Barbara Barbaro, PhD David W. Barnett, MD Vic Ben-Ezra, PhD Raﬁc F. Berbarie, MD Kris Berg, EdD Robert D. Black, MD Stuart B. Black, MD Ned Carp, MD Timothy Clark, PhD Paul Convery, MD Alan D. Cook, MD Daniel Cooper, MD Peter Dans, MD Gary Davis, MD Patricia De Leon, DO Daniel C. DeMarco, MD Alan S. Donsky, MD Kyle E. Doughty, MD Cara A. East, MD Andrew E. Epstein, MD N. A. Mark Estes III, MD Adam M. Falcone, MD Robert L. Fine, MD Gerald Fletcher, MD John S. Fordtran, MD Michael L. Foreman, MD Steve Frost, MD Swathi P. Ganaraj, MD Betsy Ann George, MD January 2014 Charles M. Gottlich, MD Michael Grant, MD Thomas C. Gunning, MD Raynal R. Hamilton, MD Baron L. Hamman, MD John Harrington, MD Robert L. Hebeler, MD Christopher A. Hebert, MD Kyle Heﬀner, MS, CPFT, CCT Howard J. Heller, MD G. Ken Hempel, MD Christian Hengstenberg, MD Joseph H. Hise, MD Martin Hoﬀman, MD Houston E. Holmes, MD John W. Hyland, MD Robert W. Inzer, MD Robert C. Kowal, MD Robert A. Kyle, MD Kennith F. Layton, MD Forrester D. Lensing, MD Marlon Levy, MD Warren E. Lichliter, MD Thomas P. Lohmann, MD Peter Louis, MD Andrew L. Masica, MD Ankit N. Mehta, MD James D. Meler, MD M. Alan Menter, MD Christopher B. Michael, MD Mark Millard, MD Eric S. Nadler, MD John C. O’Brien, MD Laura Petrey, MD Daniel Pham, MD Jonathan Philpott, MD John D. Pigott, MD, MHA John T. Preskitt, MD Charles S. Roberts, MD Robert L. Rosenthal, MD Justin Sacks, MD Sadat A. Shamim, MD A. M. James Shapiro, MD Mark Sherer, PhD William P. Shutze, MD Barry D. Silverman, MD Louis Sloan, MD Peter Snell, PhD George J. Snipes, MD Wynne M. Snoots, MD Joseph Spigel, MD Jeﬀrey Stroup, PharmD Elliot B. Tapper, MD Edward E. Taylor, MD Marc A. Tribble, MD Carlos E. Velasco, MD Jean C. Wang, MD Ann Marie Warren, PhD Allen B. Weisse, MD Matthew Westmoreland, MD Kevin Wheelan, MD Mehrzad Zarghouni, MD Steroid-resistant nephrotic syndrome secondary to primary FSGS and SMM 21

Baylor University Medical Center Proceedings January 2014, Volume 27, Number 1 | Page 23